| HOME >> MEDICINE >> TECHNOLOGY |
metastatic colorectal cancer: First
BEAT
Berry S, et al, Abstract No. 4025,
Poster No. 12.
Avastin The safety of long-term bevacizumab Monday 2 June 2008,
use: Results from the BRiTE 8:00am - 12:00pm, S
observational cohort study (OCS). Hall A1
Purdie D, et al, Abstract No. 4103,
Poster No. 14G
Avastin Safety and effectiveness of Sunday 1 June 2008,
bevacizumab (BV) and chemotherapy 8:00am - 12:00pm,
(CT) in elderly patients (pts) with E450a
metastatic colorectal cancer (mCRC):
Results from the BRiTE observational
cohort study. Kozloff M, et al,
Abstract N0. 4026, Poster No. 13
Full details of key Roche data presentations will be available on
Friday 30th May at an invitation-only media event for non-US journalists.
All abstracts are available at: http://www.asco.org/ASCO/Meetings .
Editor's note
-- Breast Cancer is one of the most common types of cancer in women, eight
to nine percent of women will develop this cancer during their
lifetime(1). Each year more than one million new cases of breast
cancer are diagnosed(2) with a death rate of over 500,000 people per
year.(3)
-- Avastin doubles the chance of a patient living without their disease
advancing (progression free survival). When used in combination with
taxanes (chemotherapy), Avastin substantially increases the efficacy of
treatment with limited impact on safety. Studies show that continual
direct VEGF inhibition with Avastin maximizes the treatment benefit for
the patient.
-- Herceptin is a humanised antibody sp
'/>"/>
| SOURCE Roche Copyright©2008 PR Newswire. All rights reserved |